Loading data...
Loading data...
Compare up to 4 stocks side by side, across all 7 of StockIQ's scoring categories.
| Category | RLYB Rallybio Corporation | AAPG Ascentage Pharma Group International - American Depository |
|---|---|---|
| Price | $17.16 +0.4% | $15.37 -0.2% |
| StockIQ Score | 62C+ Moderate Risk: Medium | 35F Weak Risk: High |
| Technical | 81A- | 13F |
| Fundamental | 30F | 35F |
| Growth | 74B | 50C- |
| Fair Value | 50C- | 38F |
| News | 86A | 50C- |
| Quality | 58C | 50C- |
| Risk | 48D+ | 40D |
Scores are based on real financial data only and do not constitute investment advice. How the score is calculated
Rallybio (RLYB) outperforms Ascentage Pharma (AAPG) in growth (74 vs. 50) and investor confidence (54 vs. 39), reflecting stronger momentum and market sentiment. However, AAPG scores slightly better in valuation (38 vs. 50) and fundamentals (35 vs. 30), though its technicals (24 vs. 53) lag far behind. Overall, RLYB shows more balanced strength, while AAPG’s weaknesses in technicals and investor rating are notable.